CLINICAL TRIALS PROFILE FOR ANDROID 10

All Clinical Trials for ANDROID 10

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02107014 ↗	Low Dose Naltrexone (LDN) Immune Monitoring	Completed	Stanford University	N/A	2014-03-01	We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.
NCT02107014 ↗	Low Dose Naltrexone (LDN) Immune Monitoring	Completed	University of Alabama at Birmingham	N/A	2014-03-01	We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.
NCT02897934 ↗	CWI and Discharge After Breast Cancer Surgery	Completed	University College Cork		2016-08-01	The objectives of this work are threefold: 1. To evaluate the analgesic efficacy of CWI in women discharged within 23 hours of major breast cancer surgery 2. To evaluate objective indices of patient recovery following anaesthesia and surgery in a 23 hour model of care 3. To evaluate patient satisfaction with their care pathway
NCT03387787 ↗	Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2	Completed	University Hospital Inselspital, Berne	Phase 2/Phase 3	2018-01-30	The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data. The GlucoTab® system was found capable to keep hospitalized diabetic patients in the recommended target range without increasing the risk for hypoglycaemic events. Insulin pharmacokinetic is a critical confounder of glycaemic variability and the main determinant of an algorithm-based decision support-system. GlucoTab® is intended for being used with a basal/bolus insulin regimen. Up to date, feasibility data are limited to the use of insulin glargine. Insulin degludec, an ultra-long acting basal insulin is characterized by a stable pharmacokinetic profile a half-life of ~25 hours. It was found equally effective to insulin glargine with respect to glycaemic control, while the incidence of (nocturnal) hypoglycaemia was smaller in patients treated with insulin degludec. Within the present study, insulin glargine will be replaced by insulin degludec, which is not yet approved for dose titration with GlucoTab®. In the present study, 15 non-critically ill T2DM patients, who were hospitalized at the University Clinic of Neurosurgery for various reasons and require insulin treatment will be recruited. Patients will be treated with insulin Tresiba and insulin Novorapid. For a maximum duration of 21 days, GlucoTab® will calculate the required insulin doses for each patient, depending on fasting plasma glucose and postprandial glucose measurements during the day. After the calculated Insulin dose has been approved by the physician, the nursing staff will give the dose to the respective patient. The present study will analyse the efficacy of GlucoTab® for glycaemic management in T2DM patients using insulin degludec.

Clinical Trial Conditions for ANDROID 10

Condition Name

Condition Name for ANDROID 10
Intervention	Trials
Breast Cancer	2
Tonsillar Bleeding	1
Leukemia	1
Type 2 Diabetes Mellitus	1

Condition MeSH

Condition MeSH for ANDROID 10
Intervention	Trials
Diabetes Mellitus	3
Pain, Postoperative	1
Renal Insufficiency	1
Breast Neoplasms	1

Clinical Trial Locations for ANDROID 10

Trials by Country

Trials by Country for ANDROID 10
Location	Trials
Canada	4
United States	3
Switzerland	2
Ireland	1

Trials by US State

Trials by US State for ANDROID 10
Location	Trials
Vermont	1
Pennsylvania	1
California	1

Clinical Trial Progress for ANDROID 10

Clinical Trial Phase

Clinical Trial Phase for ANDROID 10
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ANDROID 10
Clinical Trial Phase	Trials
Completed	3
Recruiting	3
Not yet recruiting	2

Clinical Trial Sponsors for ANDROID 10

Sponsor Name

Sponsor Name for ANDROID 10
Sponsor	Trials
Stanford University	2
University of Calgary	1
University Hospital, Geneva	1

Sponsor Type

Sponsor Type for ANDROID 10
Sponsor	Trials
Other	18

ANDROID 10 Market Analysis and Financial Projection

Last updated: April 28, 2026

Android 10: Clinical Trials Update, Market Analysis, and 10-Year Projection

Android 10 is not identifiable as a specific therapeutic drug in publicly indexed clinical trial registries or market datasets under that name alone. Without an unambiguous drug identity (active ingredient, salt, manufacturer, or ATC/UNII), clinical trial results, ongoing studies, regulatory status, and commercial forecasts cannot be produced accurately.

What clinical trials exist for “Android 10”?

No complete, verifiable clinical trial dataset can be mapped to “Android 10” as a drug without a specific pharmacologic identifier. Public clinical trial sources (for example, ClinicalTrials.gov and WHO ICTRP) require a drug name or identifier that resolves to an active ingredient; “Android 10” does not resolve to a single compound in those systems based on naming conventions alone.

What is the market for “Android 10”?

No defensible market sizing or competitive landscape can be generated for “Android 10” without identifying the underlying active ingredient and therapeutic class. Market drivers, pricing, reimbursement, and competitors depend on mechanism of action, indication, and geography, which cannot be assigned to “Android 10” without a compound-level match to established drug taxonomies.

What is the 10-year commercial projection for “Android 10”?

A 10-year projection requires:

• target indication(s)
• mechanism of action category
• dosing regimen and comparator set
• pricing and access profile
• constraints from patents, exclusivity, and pipeline headwinds

Those inputs cannot be derived from “Android 10” as a standalone name.

---

Key Takeaways

• “Android 10” cannot be mapped to a specific therapeutic drug entity using publicly indexed naming conventions, so clinical trial updates, market analysis, and forecasts cannot be produced with required factual rigor.
• Any attempt to forecast trials or revenue would require an unambiguous drug identity that links the name to an active ingredient, indication, and regulatory dossier.

---

FAQs

1. Is “Android 10” a drug, a device, or a branded formulation name?
   It is not resolvable to a single drug entity from its name alone in the clinical/market taxonomies used for defensible analysis.

2. Can you summarize ClinicalTrials.gov activity for “Android 10”?
   Not without a compound-level match to an active ingredient or trial sponsor dataset.

3. Can you estimate revenue or unit sales for “Android 10”?
   Not without identifying the therapeutic class, indication, and comparator set tied to the active ingredient.

4. How do you build a 10-year projection without an indication?
   You cannot; projections require access, pricing, and adoption drivers that are indication-specific.

5. What minimum identifiers are needed to generate a complete update?
   A resolvable active ingredient (and formulation), plus indication or regulatory mapping.

---

References

[1] ClinicalTrials.gov. (n.d.). https://clinicaltrials.gov/
[2] WHO International Clinical Trials Registry Platform (ICTRP). (n.d.). https://trialsearch.who.int/